Table 3.
Clinical and treatment characteristics of the patients according to the presence of recurrence
| Variable | Total | Recurrence |
p | |
|---|---|---|---|---|
| absent | present | |||
| Vitamin B12 level, pg/mL | 186.43±10.17 | 226.88±14.65 | 145.54±8.17 | 0.011 a |
| 25-OH vitamin D level, ng/mL | 19.01±3.25 | 17.33±2.11 | 24.28±3.65 | 0.002 b |
| Symptom duration, months | 3.76±2.56 | 3.04±2.4 | 4.65±2.61 | 0.038 a |
| Lesions, n | 1.74±0.8 | 1.55±0.8 | 1.85±0.81 | 0.079 |
| Largest lesion, mm | 39.07±15.73 | 38.26±16.39 | 41.05±15.99 | 0.020 a |
| Recurrence time, months | – | 4.6±2.28 | – | |
| Accompanying disease | <0.001 b | |||
| None | 97 (79.5) | 83 (85.6) | 14 (14.4) | |
| Autoimmune thyroid disease | 10 (8.2) | 7 (70.0) | 3 (30.0) | |
| Diabetes | 6 (4.9) | 5 (83.3) | 1 (16.7) | |
| Rheumatological disease | 9 (7.4) | 7 (77.8) | 2 (22.2) | |
| Treatment method | <0.001 b | |||
| Medical therapy alone | 28 (23.0) | 20 (50.0) | 8 (50.0) | |
| Surgery alone | 19 (15.6) | 13 (68.4) | 6 (31.6) | |
| Combined | 75 (62.4) | 70 (93.6) | 5 (6.4) | |
| Multicentricity | 54 (44.3) | 38 (70.4) | 16 (29.6) | 0.021 b |
| Erythema nodosum | 26 (21.3) | 10 (38.4) | 16 (61.5) | 0.001 b |
| Complaints | ||||
| Mass | 102 (87.1) | 87 (85.3) | 15 (14.7) | 0.319b |
| Pain | 90 (73.8) | 74 (82.2) | 16 (17.8) | 0.588b |
| Discharge | 31 (25.4) | 25 (80.6) | 6 (19.4) | 0.585b |
| Fistula | 47 (38.5) | 36 (76.6) | 11 (23.4) | 0.032 b |
| Lymphadenopathy | 30 (24.5) | 23 (76.7) | 7 (23.3) | 0.261b |
| Number of complaints | 0.016 b | |||
| <3 | 60 (49.2) | 54 (52.9) | 6 (30.0) | |
| ≥3 | 62 (50.8) | 48 (47.1) | 14 (70.0) | |
Data are presented as the mean ± SD or n (%).
a
t-test.
b
χ2 test. Bold values are statistically significant at p < 0.05.